Advertisement

Topics

Merck KGaA Highlights Mavenclad Advances In Tough Quarter

08:15 EST 10 Nov 2017 | SCRIP

Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its...

      

Related Stories

 

Original Article: Merck KGaA Highlights Mavenclad Advances In Tough Quarter

NEXT ARTICLE

More From BioPortfolio on "Merck KGaA Highlights Mavenclad Advances In Tough Quarter"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...